Table 2.
Therapies applied at inclusion in the registry and at 4-year follow-up
| At baseline N = 400 |
After 4 years N = 81 (all patients) |
||
|---|---|---|---|
| Any medication | 387 (96.8%) | 59 (72.8%) | p < 0.001 |
| NSAIDs | 344 (86%) | 32 (39.5%) | p < 0.001 |
| Systemic glucocorticoids, total | 46 (11.5%) | 3 (3.7%) | p = 0.003 |
| < 0.2 mg per kg BW | 21 (5.3) | 2 (2.5%) | p = 0.285 |
| ≥ 0.2 mg per kg BW | 33 (8.3%) | 2 (2.5%) | p = 0.068 |
| Bisphosphonates | 34 (8.5%) | 3 (3.7%) | p = 0.140 |
| DMARDs, totala | 56 (16.4%) | 21 (28.4%) | p = 0.008 |
| csDMARDs | 43 (12.6%) | 13 (17.6%) | p = 0.129 |
| Methotrexate | 30 (8.8%) | 10 (13.5%) | p = 0.21 |
| Sulfasalazine | 13 (3.8%) | 3 (4.1%) | p = 0.836 |
| bDMARD | 21 (6.1%) | 9 (12.2%) | p = 0.003 |
| Etanercept | 10 (2.9%) | 3 (4.1%) | p = 0.542 |
| Adalimumab | 11 (3.2%) | 6 (8.1%) | p = 0.05 |
NSAIDs non-steroidal anti-rheumatic drugs, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs, bDMARDs biological DMARDs, BW body weight
aInformation on DMARD therapy was available for 341 patients at baseline and 74 patients at 4-year follow-up, respectively